New Regulations and Opportunities for Foreign Investors in Healthcare Investment

Yue FU serves at Haleon as a LT member of Global Corporate Affairs, and Head of Corporate Affairs China BU. He leads corporate reputation, internal and external communications, policy and government affairs, and corporate ESG agenda.
Prior to this role, he served at Mondelez International and Carrefour respectively as VP, Corporate Affairs, with coverage extended to culture innovation, agile organization, and industry regulatory.

FU is a well respected professional in Public Affairs. He was accredited “Figure of the Year” for Dandelion Award and Golden Flag Award respectively. He is a long-serving student mentor at Shanghai Jiaotong University.

佘律师毕业于复旦大学法学院和美国加州大学伯克利分校法学院，拥有中国大陆、中国香港、美国加州和纽约州的律师执照；拥有二十多年执业经验，包括在美国硅谷从业十多年。其曾任职于多家知名国内外知名律所，包括美国奥睿硅谷和上海办公室以及高特兄弟上海办公室。自2012年10月起作为合伙人加入通力律师事务所。

佘律师专注于为中外投资人、投资基金及金融机构处理有关各类公司兼并收购、股权投资等方面的复杂交易。服务的中外投资人包括美安盛、施罗德、汇丰、摩根史坦利、三星资本、红杉、 鼎晖、信达、中信、华登国际、上海集成电路引导基金、今日资本、硅谷天堂等；也代表包括联影科技、鱼跃医疗、阿里健康、蚂蚁集团等企业。所涉行业包括投资、金融、科技、传媒、电信、网络、电商、房地产、能源、汽车、教育、医疗、食品、制造、零售及消费品等，对于各类客户的需求有着深刻的了解，擅长处理股权投资、知识产权和技术转让、策略性投资及跨境交易方面的商业及法律问题。

佘律师取得的成绩被多家业界权威机构认可, 包括 Chambers Guide (2013-2024, 先后包括全球、亚洲和/或大中华区的并购、私募股权和风险投资领先律师)、国际金融法律评论1000-金融和公司指南(2016-2023/24, 私募股权和投资基金领域的领先律师), IFLR 1000 China (2021-2023/24,投资基金、企业并购领域领先律师; 2021, 上海领先律师), AisaLaw (2016-2023, 并购和私募股权领先律师及值得关注的律师), 亚太法律500 (2014, 2016-2024, 公司与并购、投资基金、私募股权/风险投资和TMT领域的亚太领先律师)，以及亚洲法律概况(2023/24,亚太领先律师榜单(Asialaw Leading Lawyers) 。特别是被ALB评为中国十五佳女律师(2023), 入选Who’s Who Legal 全球私募基金领域专家名单(2023)和大中华区私募基金律师(2024), 被IFLR1000连续两年评为女性领军人物(2022-2023), the Legal 500评为亚太并购、私募股权投资和投资基金的领先个人(2022); 被IFLR1000 China Awards评为上海公司并购最佳律师(2021), 以及被Asian Legal Business评为中国十佳并购律师(2017); 入选Asia Lagal Awards2024年度私募股权律师的提名(2024)。

佘律师目前在上海律师协会担任并购重组委员会委员、中国基金业协会担任调解委员会委员、上海浦东新区立法律师专家、广州仲裁中心仲裁员，入选国家涉外律师库，并多次被中国证监会及中国基金业协会邀请参与专题研究课题的编写工作, 包括受邀作为基金业协会《私募股权投资基金合规手册》的主要编写人员等。

Dr. Hsiang joined Jiahui full-time in 2016, served as the Chief Medical Officer. In 2020-2024, He was the President of the Shanghai Jiahui International Hospital. Starting 2024, he became the Chairman of the Jiahui Health Executive Committee. Dr. Hsiang received his MD and Ph.D. degrees from the University of Chicago. He completed his internship and neurosurgical residency training at the University of California San Diego. Prior to joining Jiahui Health, he served as the Director of Neurosurgery at Swedish Neuroscience Institute in Seattle. With more than 30 years of clinical experience in Neurosurgery, Dr. Hsiang also specialized in minimally invasive spine surgery, and cervical arthroplasty. Dr. Hsiang is board certified in American Board of Neurological Surgery, and American Board of Spine Surgery. He is also a member of American College of Physician Executives, American Association of Neurological Surgeons, North American Spine Society and American College of Spine Surgeons. Dr. Hsiang engages in the worldwide Chinese Neurosurgery Conferences and Spine Conferences to enhance the influential and status of Chinese physicians in neurosurgery and spine surgery. Dr. Hsiang is also the Vice Chairman of International Chinese Spine Society and a council member of the Orthopedics Committee of the Chinese Association in Non-Public Medical Institutions. He is committed to encourage development and cooperation of Neurosurgery and Spine surgery in China.

Aimee leads the Healthcare sector team in MNC corporate banking at HSBC China. She has 19 years corporate banking experience, helping multinational clients to navigate the dynamic China market, and provide innovative banking products along with various regulatory changes. She also spent 2 years in HSBC Singapore as APAC Regional Relationship Manager covering corporate client relationships across multiple geographies, sectors and business types, in 20 countries in Asia. Her team includes a group of professional bankers who provide corporate lending, cash management, trade financing, FX as well as investment banking services for healthcare and consumer clients in China.